Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980649 | 0.92 | SIRT5 (0.54) | KDM4ESIRT5MAPTLMNAMAOB | |
| SCHEMBL4981482 | 0.91 | SIRT5 (0.53) | KDM4ESIRT5MAPTLMNAMAOB | |
| SCHEMBL4981533 | 0.90 | SIRT5 (0.55) | KDM4ESIRT5MAPTLMNAMAOB | |
| SCHEMBL4978956 | 0.87 | APP (0.48) | KDM4ESIRT5MAPTMAOBAPP | |
| SCHEMBL16408289 | 0.82 | SIRT5 (0.51) | SIRT5MAPTLMNASMN1; SMN2ALPG | |
| SCHEMBL9760548 | 0.81 | MAPT (0.63) | SIRT5MAPTLMNAAPPSMN1; SMN2 | |
| SCHEMBL4986888 | 0.81 | MAPT (0.71) | KDM4EMAPTLMNAMAOBTDP1 | |
| SCHEMBL2889768 | 0.81 | KDM4E (0.51) | KDM4EMAPTLMNAMAOBTDP1 | |
| SCHEMBL1665803 | 0.80 | MAPT (0.55) | KDM4EMAPTLMNAMAOBSMN1; SMN2 | |
| SCHEMBL4983931 | 0.80 | MAPT (0.53) | KDM4ESIRT5MAPTLMNAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | TRANS TECH PHARMA, INC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7329684-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7087632-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2006-02-02 | — | — | US | disclosed |
| EP-1387680-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TransTech Pharma Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2003-02-13 | — | — | US | disclosed |
| WO-2002069965-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 3269/4885SIRT5 2832/4885MAPT 539/4885 |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3282/4885SIRT5 2799/4885MAPT 474/4885 |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3269/4885SIRT5 2832/4885MAPT 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.